Empowered Patient Podcast

Nassim Usman, CEO, Catalyst Biosciences discusses the problem of Hemophilia, a rare disease in which patients have a genetic deficiency in their ability to prevent bleeding.  Currently, these patients must receive cumbersome bi-weekly IV infusions of clotting factor replacement therapy and may still bleed.  Catalyst is developing a solution to give these patients a better and more convenient treatment particularly for inhibitor patients who have developed antibodies to their replacement therapy. @catalystbio #hemophilia  #catalystbio  #subQ  #biotech Catalyst Biosciences Download the transcript here.

Sam Liu, Vice President Marketing, VivaLNK talks about the current state of health wearables and how they are powering the growth of remote patient monitoring (RPM), how continuous monitoring changes the relationship between doctors and patients, and advances in sensors which will make it easier for patients to comply with reporting and treatment plans. @viva_LNK VivaLNK.com Download the transcript here.

Chris Hutchison, CEO, Cheetah Medical discusses the importance of a non-invasive, easy to use way to assess if a patient will respond positively to IV fluids in emergencies and in other critical care situations, and how Cheetah Medical devices are empowering healthcare providers by providing real time, continuous information to allow them to dose fluids safely, dynamically and with confidence they are doing no harm. @Cheetah_Medical #IVFluid  #FluidManagement  #sepsis  #criticalcare Cheetah Medical Download the transcript here.

Alexis Peyroles, CEO, OSE Immunotherapeutics talks about the important role the immune system plays in the development of a number of diseases.  OSE is a biotechnology company focused on the therapies that control the immune system for treatment of cancers and autoimmune diseases.  We discuss how drugs that regulate the immune system can provide the basis for the next generation of oncology and autoimmune disease treatments. @OSEImmuno #autoimmune  #ImmunoOncology  #Oncology  #OSE_IMMUNO OSE Immunotherapeutics Download the transcript here  

Dr. Tony Fiorino, Chief Medical Officer, electroCore discusses the challenge of managing and preventing primary and secondary headaches particularly migraines, the science behind the electroCore non-invasive vagus nerve stimulator gammaCore(TM) and understanding the neurological triggers and mechanisms of headache disorders. @electroCoreVNS #migraine #headaches #neuromodulation #non-invasive #vagusnervestimulation #neurology electroCore.com Download the transcript here.

Dr. Costas Hadjipanayis, Director of Neurosurgical Oncology for Mount Sinai Beth Israel Hospital discusses his experience working with the advanced robotically-controlled digital microscope, Modus V, from Synaptive Medical and how this technology was used recently to successfully remove a 19-year old woman's rare brain tumor.  Dr. H talks about the advantages to using this technology prior to surgery and during surgery, and how doctors need to think about embracing new devices and techniques to more accurately address medical challenges. @SynaptiveMed #BrainSurgery  #Neurosurgery  #PrecisionMedicine  #RoboticSurgery  #ModusV Synaptive Medical Download the transcript here.

Isaac Israel, CEO, Kitov Pharmaceuticals talks about how the development of new cancer treatments is an active and rapidly changing field and how Kitov is focusing on making cancer treatments more effective for patients.  They are developing combination therapies that can help overcome cancers' ability to develop resistance to treatment.  Kitov is working on two innovative cancer treatments soon to be advanced to clinical trials. #oncology #immunoOncology Kitov Pharmaceuticals Download the transcript here.  

Gilead Raday, COO, Redhill Biopharma, a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases talks about the growing problem of antibiotic resistance and the challenges this presents treating H. pylori infections, which affects about half of the global population.  Redhill is working to bring Talicia, a new treatment for H. pylori to market potentially this year giving patients a new effective option for H. pylori infection. #RDHL  $RDHL #Hpylori #IBD #GI @RedHillBio Redhillbio.com Download the transcript here.

Paul Kohlhaas, Founder, Molecule is passionate about creating a network for the decentralization of the process of researching new molecules and developing new molecular compounds using blockchain to track and reward all those who participate.  With the current pharma innovation crisis and rising costs of drug development, new methods are needed to break down silos and overcome challenges of drug resistance and treating rare diseases. @molecule_to Molecule.to Download the transcript here.

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland.  She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors. @TiburioT #neuroendocrine  #pituitaryadenoma  #chiefmedicalofficer  #raredisease  #NFPA  Tiburio Therapeutics Download the PDF file of the interview here.